跳至主要内容
临床试验/JPRN-jRCTs031220728
JPRN-jRCTs031220728招募中Unknown

Exploratory study to compare AMPA receptors changes during rehabilitation with or without T-817MA measured with [11C]K-2 PET combined with Japic-104711 data - Additional T-817 AMPA-PET

Abe Hiroki0 个研究点目标入组 2 人开始时间: 2023年3月24日最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
2

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 < 85age old(—)
性别
All

入选标准

  • (1) Males and females aged 20 to 85 at the time of informed consent
  • (2) Japanese living in Japan
  • (3) Patients diagnosed with first-onset stroke (excluding subarachnoid hemorrhage) by MRI or CT (Patients with a history of transient ischemic attack and asymptomatic cerebral infarction are eligible for inclusion)
  • (4)Patients who can undergo the first AMPA-PET imaging within 22 to 56 days after stroke onset as day 1.
  • (5) Patients with unilateral upper limb paralysis and a total FMA (upper limb motor function) score of 47 or less on the paralyzed side
  • (6) Patients who can be hospitalized and undergo rehabilitation after obtaining consent until the second AMPA-PET imaging
  • (7) Patients who can obtain written informed consent to participate in this study from themselves. It is possible to have a fair witness as a third party who agrees to participate in.

排除标准

  • (1) Patients who cannot answer questions 1) or 2) below or respond to instructions 3) or 4)
  • 1) Month name of the month, 2) Age, 3) Eyes open and closed, 4) Hands-off handshake on healthy side
  • (2) Severe higher brain dysfunction, severe sensory disturbance, depression, cognitive dysfunction such as schizophrenia, and psychiatric disorders patient
  • (3) Patients with pain in the upper extremities that disturbs sleep
  • (4) Patients unable to jointly move the upper extremities or collectively flex the fingers
  • (5) Patients with a baseline FMA increase of 1 point or less or 9 points or more from the screening FMA value
  • (6) Hepatic dysfunction (either AST, ALT, or ALP >= 2.5 times the upper limit of institutional reference) or renal dysfunction (serum Cr is 2.0 mg/dl or higher)
  • (7) Complications that make rehabilitation difficult for the upper extremities (severe heart disease, uncontrolled hypertension, pulmonary embolism, severe orthopedic disease)
  • (8) Patients with a history or complication of epilepsy
  • (9) Patients taking perampanel or topiramate (drugs with AMPA receptor antagonism)
  • (10) Patients who developed convulsions after stroke
  • (11) Patients who are pregnant or may be pregnant
  • (12) Breast-feeding patients
  • (13) Patients who cannot actively participate in rehabilitation
  • (14) Patients who are contraindicated for MRI imaging (patients with non-MRI compatible cardiac pacemakers, dental implants, patients with non-removable metal inclusions such as tattoos, patients with severe claustrophobia) )
  • (15) Patients participating in other clinical trials/clinical studies (excluding observational studies) during the study participation period
  • (16) Patients who have participated in a clinical trial of T-817MA in the past
  • (17) Patients with alcohol hypersensitivity
  • (18) Patients who are judged to be inappropriate as research subjects by the principal investigator or subinvestigator

研究者

发起方
Abe Hiroki

相似试验